- ProductsInvestment SuiteExclusiveFeatures
- PlatformTrading PlatformsFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnStockshaalaResourceInvesting GuideEvents
- Partner
- Support
Products
Platform
Research
Market
Learn
Compare Aditya Birla Sun Life Pharma & Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.33 | 1.9 |
NAV | ₹30.04 | ₹38.75 |
Fund Started | 20 Jun 2019 | 25 Jun 2018 |
Fund Size | ₹818.33 Cr | ₹5295.32 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
2.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.33
1.9
NAV
₹30.04
₹38.75
Fund Started
20 Jun 2019
25 Jun 2018
Fund Size
₹818.33 Cr
₹5295.32 Cr
Exit Load
Exit load of 1% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 13.02% | 24.04% |
3 Year | 21.48% | 28.02% |
5 Year | 19.37% | 25.72% |
1 Year
13.02%
24.04%
3 Year
21.48%
28.02%
5 Year
19.37%
25.72%
Holding Analysis
Equity | 98.22% | 96.34% |
Cash | 1.78% | 3.66% |
Equity
98.22%
96.34%
Cash
1.78%
3.66%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 15.37% |
Cipla Ltd. | 8.09% |
Apollo Hospitals Enterprise Ltd. | 7.24% |
Torrent Pharmaceuticals Ltd. | 6.49% |
Abbott India Ltd. | 5.97% |
Aurobindo Pharma Ltd. | 5.13% |
Lupin Ltd. | 5.02% |
Fortis Healthcare Ltd. | 4.42% |
Ajanta Pharma Ltd. | 4.28% |
Ipca Laboratories Ltd. | 3.77% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.23% |
Dr. Reddy's Laboratories Ltd. | 9.50% |
Cipla Ltd. | 8.63% |
Divi's Laboratories Ltd. | 7.81% |
Aurobindo Pharma Ltd. | 7.05% |
Lupin Ltd. | 4.43% |
Alkem Laboratories Ltd. | 4.30% |
Zydus Lifesciences Ltd. | 3.89% |
Gland Pharma Ltd. | 3.62% |
Syngene International Ltd. | 2.20% |
Fund Manager
Name | Dhaval Joshi | Dharmesh Kakkad |
Start Date | 21 Nov 2022 | 23 Feb 2021 |
Name
Dhaval Joshi
Dharmesh Kakkad
Start Date
21 Nov 2022
23 Feb 2021
About Fund
Description | The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 20 Jun 2019 | 25 Jun 2018 |
Description
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
20 Jun 2019
25 Jun 2018